By Olivia Hart

Photodynamic therapy cleared regulatory approval for basal cell carcinoma, the most common skin cancer in the United States, MedPage Today reported in coverage tied to researchers at Dartmouth's Geisel School of Medicine.

What does the approval cover?

The label change pulls PDT inside the formal BCC toolkit rather than leaving it on the off-label shelf.

The modality uses a topically applied photosensitizer — aminolevulinic acid leads the field, with its methyl ester as a close second — left to incubate over the lesion for a defined period, typically three to six hours, before illumination at a calibrated wavelength.

Red light at 633 nm penetrates deeper and better suits nodular disease. Blue light at 417 nm is the standard for actinic keratoses and superficial lesions.

Once illuminated, the photosensitizer generates reactive oxygen species that destroy malignant cells while sparing most adjacent normal tissue. The cosmetic profile often beats surgery on the face, scalp, and chest, where scarring carries visible weight.

PDT has lived in U.S. dermatology clinics for more than two decades under approved indications for actinic keratoses and, in some formulations, acne. BCC has been treated off-label on a case-by-case basis for years. The new label establishes a regulatory and reimbursement pathway that off-label use could not.

What changes for dermatology practices?

Practices operating red-light or blue-light PDT units will find their existing workflow fits the new indication without fresh equipment purchases. The mechanics stay the same. Documentation, coding, and payer language change.

Surgical excision and Mohs micrographic surgery remain standard for invasive BCC, particularly on the face, hands, and lower legs. PDT slots in as a non-surgical alternative for patients with surgical contraindications, anticoagulation issues, multiple lesions in one session, or tumors meeting superficial histologic criteria.

Recurrence rates for surgery still run lower than for PDT on matched lesions. Patient selection carries weight.

Three operational variables will determine rollout pace. First, which photosensitizer formulation the approval names. Second, the wavelength and fluence parameters the label endorses. Third, how quickly Medicare and the major commercial payers update medical policies to reflect the new indication.

MedPage Today's coverage, as cited here, did not detail the formulation or the device specifications behind the approval.

What should clinicians watch next?

The next twelve months will likely bring peer-reviewed trial data behind the regulatory decision, American Academy of Dermatology guideline revisions, and payer policy updates that decide whether in-office PDT shifts from a case-by-case prior-authorization procedure to a routinely reimbursed benefit.

Practices that have run PDT on a small scale can scale up once payer policy catches up. Practices that have stayed on the sidelines now have a clear opening to evaluate the modality against their existing BCC volume before payer policy hardens around a labeled standard of care.

For community dermatology clinics weighing a PDT expansion, the cheapest move is to audit the lesions currently referred out for surgery or radiation and ask which of them meet the superficial criteria the new label is likely to formalize.